

**Key figures** in millions of CHF

	Six months ended 30 June		% change		% of sales	
	2006 (mCHF)	2005 (mCHF)	(CHF)	(LC)	2006	2005
Sales	19,849	16,622	+19	+16		
Research and development	3,063	2,543	+20	+17	15.4	15.3
EBITDA <sup>1)</sup>	7,061	5,592	+26	+23	35.6	33.6
Operating profit before exceptional items	5,805	4,454	+30	+27	29.2	26.8
Profit before exceptional items <sup>2)</sup>	4,528	3,418	+32		22.8	20.6
Net income	4,543	3,328	+37		22.9	20.0
Core EPS <sup>3)</sup>	4.90	3.80	+29			

	30 June 2006	31 December 2005	30 June 2005
Net cash	11,965	11,215	8,448
Equity	41,520	40,158	37,478
Equity ratio	61.0%	58.0%	60.1%

<sup>1)</sup> EBITDA: Earnings before exceptional items and before financial income, financing costs, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment

<sup>2)</sup> Continuing businesses

<sup>3)</sup> See page 48 of the Half-Year Report for definition of Core EPS

LC = local currencies

For all further tables, please see next pages and the Half-Year Report 2006:  
[www.roche.com/fig\\_halfyearrep\\_2006](http://www.roche.com/fig_halfyearrep_2006)

A. Sales January to June 2006 and 2005

	2006	2005	% change	
	CHF m	CHF m	In CHF	In local currencies
January – June				
<b>Pharmaceuticals Division</b>	15,577	12,652	+23	+19
Roche Pharmaceuticals	9,670	7,978	+21	+17
Genentech	4,223	2,867	+47	+39
Chugai	1,684	1,807	-7	-4
<b>Diagnostics Division</b>	4,272	3,970	+8	+4
<b>Roche Group</b>	19,849	16,622	+19	+16

B. Quarterly local sales growth by Division in 2005 and 2006

	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005
<b>Pharmaceuticals Division</b>	+21	+34	+19	+19
Roche Pharmaceuticals	+17	+32	+19	+15
Genentech	+42	+49	+40	+39
Chugai	+7	+22	-8	+1
<b>Diagnostics Division</b>	+6	+3	+3	+5
<b>Roche Group</b>	+17	+26	+15	+16

C. Quarterly sales by Division in 2005 and 2006

CHF millions	Q2 2005	Q3 2005	Q4 2005	Q1 2006	Q2 2006
<b>Pharmaceuticals Division</b>	6,497	6,782	7,834	7,739	7,838
Roche Pharmaceuticals	4,119	4,191	4,786	4,821	4,849
Genentech	1,526	1,765	1,982	2,056	2,167
Chugai	852	826	1,066	862	822
<b>Diagnostics Division</b>	2,035	2,038	2,235	2,091	2,181
<b>Roche Group</b>	8,532	8,820	10,069	9,830	10,019

1. Top 20 Pharmaceuticals Division product sales<sup>1</sup> and local growth<sup>2</sup> in H1 2006: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	2,348	16%	1,309	11%	89	1%	950	25%
Herceptin	1,813	105%	775	116%	70	30%	968	106%
Avastin	1,389	119%	1,043	83%	-	-	346	405%
NeoRecormon/Epogin	1,100	1%	-	-	342	-6%	758	5%
Tamiflu	961	62%	276	254%	179	-30%	506	104%
CellCept	891	7%	436	17%	15	18%	440	-3%
Pegasys	724	2%	218	-12%	33	-18%	473	13%
Xeloda	472	27%	182	31%	13	-2%	277	27%
Tarceva	367	143%	249	66%	-	-	118	3818%
Xenical	363	12%	62	20%	-	-	301	10%
Xolair	257	34%	257	34%	-	-	-	-
Kytril	254	6%	100	2%	65	8%	89	9%
Nutropin	244	-1%	237	-1%	-	-	7	3%
Cymevene/Valcyte	223	16%	114	17%	-	-	109	15%
Rocephin	216	-66%	17	-96%	29	-1%	170	-17%
Pulmozyme	212	9%	122	6%	-	-	90	14%
Neutrogen	188	15%	-	-	188	15%	-	-
Activase/TNKase	178	20%	156	19%	-	-	22	24%
Bonviva/Boniva	167	661%	147	569%	-	-	20	-
Dilatrend	159	-7%	-	-	-	-	159	-7%
New products not covered in Top 20								
Fuzeon	143	19%	69	19%	-	-	74	20%
Copegus	117	-46%	12	-89%	-	-	105	-11%
Evista	64	60%	-	-	64	60%	-	-
Raptiva	62	0%	62	0%	-	-	-	-
Renagel	29	15%	-	-	29	15%	-	-
Lucentis	13	-	13	-	-	-	-	-
Actemra	2	-	-	-	2	-	-	-
Femara	1	-	-	-	1	-	-	-

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined <sup>2</sup> versus H1 2005

## 2. Top 20 Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> in 2005 and 2006

	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005
MabThera/Rituxan	18%	23%	16%	16%
Herceptin	57%	77%	107%	103%
Avastin	107%	127%	141%	102%
NeoRecormon/Epogin	6%	12%	3%	0%
Tamiflu	148%	631%	37%	133%
CellCept	28%	25%	15%	-1%
Pegasys	15%	17%	2%	3%
Xeloda	44%	47%	35%	21%
Tarceva	-	722%	182%	119%
Xenical	9%	9%	16%	8%
Xolair	51%	57%	39%	30%
Kytril	14%	5%	18%	-4%
Nutropin	3%	4%	-3%	1%
Cymevene/Valcyte	22%	23%	21%	12%
Rocephin	-54%	-55%	-69%	-63%
Pulmozyme	15%	15%	14%	4%
Neutrogin	20%	18%	19%	12%
Activase/TNKase	9%	23%	19%	21%
Bonviva/Boniva	-	-	-	323%
Dilatrend	-12%	3%	-6%	-8%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

### 3. Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> US in 2005 and 2006

	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005
MabThera/Rituxan	14%	20%	7%	16%
Herceptin	70%	99%	123%	110%
Avastin	78%	88%	96%	72%
NeoRecormon/Epogin	-	-	-	-
Tamiflu	132%	390%	414%	143%
CellCept	52%	44%	32%	6%
Pegasys	9%	14%	-14%	-10%
Xeloda	51%	64%	40%	24%
Tarceva	-	528%	95%	46%
Xenical	20%	18%	24%	15%
Xolair	51%	57%	39%	30%
Kytril	20%	-2%	31%	-20%
Nutropin	3%	4%	-3%	1%
Cymevene/Valcyte	17%	14%	15%	20%
Rocephin	-75%	-81%	-96%	-96%
Pulmozyme	17%	15%	12%	0%
Neutrogin	-	-	-	-
Activase/TNKase	10%	25%	19%	19%
Bonviva/Boniva	-	-	-	262%
Dilatrend	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

4. Pharmaceuticals Division quarterly local product sales growth Japan<sup>1</sup> in 2005 and 2006

	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005
MabThera/Rituxan	1%	5%	3%	-1%
Herceptin	15%	26%	31%	30%
Avastin	-	-	-	-
NeoRecormon/Epogin	2%	7%	-3%	-9%
Tamiflu	-	733%	-33%	367%
CellCept	18%	22%	15%	20%
Pegasys	4%	3%	-11%	-24%
Xeloda	27%	20%	1%	-5%
Tarceva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Kytril	10%	11%	6%	9%
Nutropin	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Rocephin	17%	14%	-11%	8%
Pulmozyme	-	-	-	-
Neutrogin	20%	18%	19%	12%
Activase/TNKase	-	-	-	-
Bonviva/Boniva	-	-	-	-
Dilatrend	-	-	-	-

<sup>1</sup> Chugai

5. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World<sup>1</sup> in 2005 and 2006

	Q3 2005 vs. Q3 2004	Q4 2005 vs. Q4 2004	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005
MabThera/Rituxan	29%	32%	30%	20%
Herceptin	51%	69%	105%	107%
Avastin	1755%	1203%	654%	294%
NeoRecormon/Epogin	9%	16%	6%	5%
Tamiflu	158%	864%	88%	124%
CellCept	9%	9%	2%	-7%
Pegasys	20%	23%	12%	13%
Xeloda	41%	37%	34%	20%
Tarceva	-	-	-	2566%
Xenical	7%	7%	14%	7%
Xolair	-	-	-	-
Kytril	9%	9%	13%	4%
Nutropin	-6%	-5%	12%	-4%
Cymevene/Valcyte	27%	36%	27%	5%
Rocephin	-23%	-10%	-24%	-9%
Pulmozyme	11%	16%	18%	10%
Neutrogin	-	-	-	-
Activase/TNKase	6%	6%	14%	33%
Bonviva/Boniva	-	-	-	-
Dilatrend	-12%	3%	-6%	-8%

<sup>1</sup> Roche Pharmaceuticals

## 6. Top Pharmaceuticals Division quarterly product sales<sup>1</sup> in 2005 and 2006

CHF millions	Q2 2005	Q3 2005	Q4 2005	Q1 2006	Q2 2006
MabThera/Rituxan	1,015	1,057	1,153	1,146	1,202
Herceptin	460	591	704	861	952
Avastin	347	486	572	676	713
NeoRecormon/Epogin	570	564	602	535	565
Tamiflu	156	279	699	601	360
CellCept	430	441	464	454	437
Pegasys	355	350	373	350	374
Xeloda	190	213	228	238	234
Tarceva	88	101	141	172	195
Xenical	165	162	161	181	182
Xolair	100	104	123	124	133
Kytril	130	130	135	130	124
Nutropin	122	116	128	118	126
Cymevene/Valcyte	99	100	109	110	113
Rocephin	284	152	161	110	106
Pulmozyme	97	100	107	109	103
Neutrogen	89	97	98	93	95
Activase/TNKase	72	84	87	88	90
Bonviva/Boniva	21	14	51	75	92
Dilatrend	84	79	80	81	78
<b>New products not covered in Top 20</b>					
Fuzeon	66	62	81	72	71
Copegus	109	107	87	60	57
Evista	25	28	35	27	37
Raptiva	31	28	30	31	31
Renagel	15	15	16	13	16
Lucentis	-	-	-	-	13
Actemra	-	-	1	1	1
Femara	-	-	-	-	1

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

## 7. Pharmaceuticals Division quarterly product sales<sup>1</sup> in US in 2005 and 2006

CHF millions	Q2 2005	Q3 2005	Q4 2005	Q1 2006	Q2 2006
MabThera/Rituxan	573	612	672	634	675
Herceptin	186	271	321	375	400
Avastin	300	409	462	516	527
NeoRecormon/Epogin	-	-	-	-	-
Tamiflu	44	109	210	168	108
CellCept	200	225	244	221	215
Pegasys	124	124	137	103	115
Xeloda	71	83	99	92	90
Tarceva	86	92	108	120	129
Xenical	24	24	26	34	28
Xolair	100	104	123	124	133
Kytril	54	54	56	57	43
Nutropin	119	113	124	114	123
Cymevene/Valcyte	49	53	57	55	59
Rocephin	180	54	48	9	8
Pulmozyme	57	60	63	64	58
Neutrogen	-	-	-	-	-
Activase/TNKase	64	73	77	78	78
Bonviva/Boniva	21	13	48	69	78
Dilatrend	-	-	-	-	-
<b>New products not covered in Top 20</b>					
Fuzeon	29	34	44	33	36
Copegus	53	53	35	6	6
Evista	-	-	-	-	-
Raptiva	31	28	30	31	31
Renagel	-	-	-	-	-
Lucentis	-	-	-	-	13
Actemra	-	-	-	-	-
Femara	-	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

### 8. Pharmaceuticals Division quarterly product sales<sup>1</sup> in Japan in 2005 and 2006

CHF millions	Q2 2005	Q3 2005	Q4 2005	Q1 2006	Q2 2006
MabThera/Rituxan	52	50	59	41	48
Herceptin	31	32	38	32	38
Avastin	-	-	-	-	-
NeoRecormon/Epogin	209	203	232	160	182
Tamiflu	3	2	133	170	9
CellCept	7	7	9	7	8
Pegasys	23	23	25	17	16
Xeloda	8	8	8	6	7
Tarceva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Kytril	35	35	40	29	36
Nutropin	-	-	-	-	-
Cymevene/Valcyte	-	-	-	-	-
Rocephin	15	14	17	13	16
Pulmozyme	-	-	-	-	-
Neutrogen	89	97	98	93	95
Activase/TNKase	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Dilatrend	-	-	-	-	-
<b>New products not covered in Top 20</b>					
Fuzeon	-	-	-	-	-
Copegus	-	-	-	-	-
Evista	25	28	35	27	37
Raptiva	-	-	-	-	-
Renagel	15	15	16	13	16
Lucentis	-	-	-	-	-
Actemra	-	-	1	1	1
Femara	-	-	-	-	1

<sup>1</sup> Chugai

9. Pharmaceuticals Division quarterly product sales in Europe/Rest of World<sup>1</sup> in 2005 and 2006

CHF millions	Q2 2005	Q3 2005	Q4 2005	Q1 2006	Q2 2006
MabThera/Rituxan	390	395	422	471	479
Herceptin	243	288	345	454	514
Avastin	47	77	110	160	186
NeoRecormon/Epogin	361	361	370	375	383
Tamiflu	109	168	356	263	243
CellCept	223	209	211	226	214
Pegasys	208	203	211	230	243
Xeloda	111	122	121	140	137
Tarceva	2	9	33	52	66
Xenical	141	138	135	147	154
Xolair	-	-	-	-	-
Kytril	41	41	39	44	45
Nutropin	3	3	4	4	3
Cymevene/Valcyte	50	47	52	55	54
Rocephin	89	84	96	88	82
Pulmozyme	40	40	44	45	45
Neutrogen	-	-	-	-	-
Activase/TNKase	8	11	10	10	12
Bonviva/Boniva	-	1	3	6	14
Dilatrend	84	79	80	81	78
<b>New products not covered in Top 20</b>					
Fuzeon	37	28	37	39	35
Copegus	56	54	52	54	51
Evista	-	-	-	-	-
Raptiva	-	-	-	-	-
Renagel	-	-	-	-	-
Lucentis	-	-	-	-	-
Actemra	-	-	-	-	-
Femara	-	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals